Comparative Pharmacology
Head-to-head clinical analysis: LACRISERT versus MIEBO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LACRISERT versus MIEBO.
LACRISERT vs MIEBO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LACRISERT (hydroxypropyl cellulose ophthalmic insert) acts as a lubricant to stabilize and thicken the precorneal tear film, prolonging tear film breakup time and protecting the ocular surface. It does not have pharmacological activity.
MIEBO (perfluorohexyloctane) is a semifluorinated alkane that forms a protective lipid layer on the ocular surface, reducing tear evaporation and improving tear film stability. It also acts as a lubricant.
One 5 mg ophthalmic insert placed into the inferior cul-de-sac of the eye once daily.
Not applicable. MIEBO (perfluorohexyloctane) is an ophthalmic emulsion; one drop in each eye four times daily.
None Documented
None Documented
Not applicable; local ocular insert, no systemic half-life.
Terminal elimination half-life is 12-18 hours; clinically relevant for once-daily dosing.
Not systemically absorbed; no renal or biliary elimination.
Primarily renal excretion of unchanged drug (approximately 60-70%) and hepatic metabolism with biliary/fecal elimination (30-40%).
Category C
Category C
Ophthalmic Lubricant
Ophthalmic Lubricant